Full-Time
Confirmed live in the last 24 hours
Genetic testing and diagnostics solutions provider
$137.2k - $171.5k/yr
Senior
Company Historically Provides H1B Sponsorship
Austin, TX, USA + 1 more
More locations: San Carlos, CA, USA
Preferred location is Austin, Texas for direct observation of the software in the lab and obtaining real-time user feedback.
Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through precise genetic insights.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Austin, Texas
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Flexible medical plans
Investment options
Time off
Workplace perks
Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas. Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas.Austin, Texas — According to state and local development sources, Natera plans to invest $9,900,000.00 to build out 30,000 square feet of new space in Austin. The company plans to occupy the new space at 13011A McCallen Pass in Austin, on or about January 1, 2026. According to the company website Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, womens health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment
Natera announces broad clinical launch of ultra-sensitive signatera(tm) genome MRD test.
DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).
AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.
Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.